PerjePerjeta 420 mg Injection contains Pertuzumab, a monoclonal antibody used in combination therapy for the treatment of HER2-positive breast cancer, including metastatic and early-stage disease. It works by blocking HER2 receptor dimerization, helping inhibit cancer cell growth and enhancing the effect of other HER2-targeted therapies. This product is manufactured by Roche.
Side Effects:
Common side effects include diarrhea, hair thinning, nausea, fatigue, rash, and decreased appetite. Some patients may experience low white blood cell counts, infusion-related reactions, or mild peripheral neuropathy. Serious but less common reactions include cardiac dysfunction, severe hypersensitivity, fever with neutropenia, and severe diarrhea. Close monitoring is required in patients with heart disease or those receiving other HER2-targeted medicines.